This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Barclays analyst Gena Wang initiated coverage on Cytokinetics, Incorporated CYTK with an Overweight rating and announced a price target of $5. Cytokinetics shares closed at $38.00 on Wednesday. See how other analysts view this stock.
  • Lake Street analyst Jacob Stephan initiated coverage on ACCESS Newswire Inc. ACCS with a Buy rating and announced a price target of $15. ACCESS Newswire shares closed at $8.65 on Wednesday. See how other analysts view this stock.

Considering buying CYTK stock? Here’s what analysts think:

Read This Next:

Photo via Shutterstock

ACCS Logo
ACCSACCESS Newswire Inc
$8.40-2.04%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
-
Growth
3.93
Quality
-
Value
28.11
Price Trend
Short
Medium
Long
Got Questions? Ask
How will Cytokinetics, Incorporated achieve its price target?
What impact will analyst ratings have on CYTK shares?
Which investors are most likely to back ACCESS Newswire after the upgrade?
Could ACCESS Newswire attract institutional investors now?
How might Cytokinetics leverage its Overweight rating?
What sectors could benefit from investor confidence in CYTK?
Will other analysts follow suit on Cytokinetics?
How will the market respond to ACCESS Newswire's price target?
What risks does Cytokinetics face with its bullish outlook?
Which competitors might be impacted by Cytokinetics's performance?
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:
Comments
Loading...